At 24 Months1
- The INTRACEPT Study randomized 140 patients (66 BVN ablation vs 74 SC) across 20 sites. Enrollment was stopped early due to statistical superiority at the pre-specified interim analysis; as a result, the control arm was offered early active treatment. Primary results were published in 2019, showing a statistically significant difference between the Intracept arm and the standard care arm for the primary endpoint and all secondary endpoints at three months post-procedure.
- The publication reports outcomes for 58 patients (88% retention rate) in the Intracept treatment arm that completed a 24-month follow up visit.
Mean ODI at 24 Months
Patients in the Intracept Procedure treatment arm realized a 28.5 point (p<0.001) reduction in mean Oswestry Disability Index (ODI) from baseline to 24 months. Significant and sustained reductions in mean ODI were demonstrated after treatment in all BVN ablation patients.
VAS Pain Reduction by Quadrant Improvement
Responder Rates to 24 Months
1. Koreckij T, Kreiner S, Khalil JG, Smuck M, Markman J, Garfin S. Prospective, randomized, multicenter study of intraosseous basivertebral nerve ablation for the treatment of chronic low back pain: 24-month treatment arm results. NASSJ. Published online October 26, 2021. DOI: https://doi.org/10.1016/j.xnsj.2021.100089